[go: up one dir, main page]

WO2025096929A1 - Dispositif de photothérapie à commutation de longueur d'onde - Google Patents

Dispositif de photothérapie à commutation de longueur d'onde Download PDF

Info

Publication number
WO2025096929A1
WO2025096929A1 PCT/US2024/054102 US2024054102W WO2025096929A1 WO 2025096929 A1 WO2025096929 A1 WO 2025096929A1 US 2024054102 W US2024054102 W US 2024054102W WO 2025096929 A1 WO2025096929 A1 WO 2025096929A1
Authority
WO
WIPO (PCT)
Prior art keywords
infant
processor circuitry
light
emitted light
skin tone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/054102
Other languages
English (en)
Inventor
Peter Broer
Alan Greszler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumitex Inc
Original Assignee
Lumitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumitex Inc filed Critical Lumitex Inc
Publication of WO2025096929A1 publication Critical patent/WO2025096929A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0621—Hyperbilirubinemia, jaundice treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods

Definitions

  • Phototherapy is a common and effective treatment for neonatal jaundice, a condition where a newborn has high levels of bilirubin in the blood.
  • the key principle behind phototherapy is to use light to transform bilirubin into isomers that are more water-soluble and can be excreted by the infant's body without the need for further metabolism by the liver.
  • the wavelength of light used in phototherapy determines effectiveness of the treatment.
  • the most effective wavelength range for converting bilirubin is between 430 and 490 nanometers, which falls within the blue-green spectrum. This range is effective because it corresponds to the absorption peak of bilirubin.
  • the present disclosure provides a phototherapy system for treating neonatal jaundice in an infant by controlling phototherapy based on properties of the infant such that the infant receives a therapeutic effect. While a number of features are described herein with respect to embodiments of the invention; features described with respect to a given embodiment also may be employed in connection with other embodiments. The following description and the annexed drawings set forth certain illustrative embodiments of the invention. These embodiments are indicative, however, of but a few of the various ways in which the principles of the invention may be employed.
  • FIG. 1 is a block diagram of a phototherapy system.
  • FIG. 2 is an exemplary graph showing absorbance of light by red blood cells.
  • FIG. 3 is an exemplary graph showing absorbance of light by melanin and bilirubin.
  • FIG. 4 is an exemplary graph showing the relationship between a center wavelength of the light emitted by the light source of FIG. 1 and hematocrit level as a sensed parameter.
  • FIG. 5 is an exemplary graph showing the relationship between a center wavelength of the light emitted by the light source of FIG. 1 and hematocrit level as a sensed parameter.
  • each element with a reference number is similar to other elements with the same reference number independent of any letter designation following the reference number.
  • a reference number with a specific letter designation following the reference number refers to the specific element with the number and letter designation and a reference number without a specific letter designation refers to all elements with the same reference number independent of any letter designation following the reference number in the drawings.
  • the present disclosure provides a phototherapy system for treating neonatal jaundice in an infant by controlling phototherapy based on properties of the infant.
  • the system includes processor circuitry for altering control variables received by a light source based on sensor measurements of bilirubin levels, skin tone, or hematocrit levels.
  • a phototherapy system 10 is shown for treating neonatal jaundice in an infant by controlling phototherapy based on properties of the infant.
  • the phototherapy system 10 controls the phototherapy such that the infant 11 receives a therapeutic effect.
  • the phototherapy system includes a light source 12, processor circuitry 14, and a sensor 16.
  • the light source 12 emits light 18 (within a wavelength range) for illuminating the infant.
  • the light source 12 modifies properties of the emitted light based on control variables 20 received from the processor circuitry 14.
  • the processor circuitry 14 alters the control variables 20 received by the light source to modify properties of the emitted light 20 based on sensed parameters 22 output by the sensor 16.
  • the sensor 16 measures as sensed parameters 22 at least one of bilirubin levels in the infant, skin tone of the infant, or hematocrit levels of the infant.
  • the processor circuitry 14 uses the sensed parameters 22 to modify at least one of the wavelength, intensity, timing, or duration of illumination of the light 18. In this way, the processor circuitry 14 alters the control variables 20 based on the sensed parameters 22 such that the wavelength range of the emitted light 18 is optimized to reduce the bilirubin levels of the infant.
  • the rationale behind the wavelength shifting executed by the processor circuitry 14 may be to identify and utilize a wavelength for phototherapy that is most optimal for the specific infant under treatment.
  • This wavelength adjustment can be effected by manipulating the wavelengths of light emitted by the light source or through the deployment of optical filters, such as band-pass filters.
  • the wavelength range of the emitted light 18 may include a center wavelength and a band of wavelengths around the center wavelength.
  • the band may have a 20 nm width, such that a majority of the emitted light is within plus or minus 10 nm of the center wavelength.
  • the wavelength range may be within 430-490 nm.
  • the processor circuitry may be configured (as is described in further detail below) to shift the wavelength of the emitted light from nearer 450 nm to closer to 490 nm (such as approximately 480 nm) allowing for more effective phototherapy at higher hematocrit levels.
  • 490 nm such as approximately 480 nm
  • melanin’s absorption of light decreases towards the higher end of the range (i.e., approaching 490 nm).
  • the processor circuitry 14 may increase the wavelength of emitted light 18 to increase a portion of the emitted light that has a therapeutic effect (i.e., reducing an amount of non-therapeutic light).
  • An exemplary relationship between center wavelength of the emitted light and skin tone (increasing melanin content to the right) is shown in FIG. 4.
  • the adjustment of the center wavelength by the processor circuitry 14 in response to increasing skin tone or hematocrit levels can follow various mathematical relationships, depending on the desired therapeutic outcome and empirical data. For example, the change in center wavelength may be directly proportional to the measured parameter, resulting in a linear relationship.
  • the processor circuitry 14 may employ a non-linear relationship, such as exponential or logarithmic, to adjust the center wavelength more precisely based on how the absorption characteristics change with the measured parameters.
  • ⁇ c ⁇ 0 ⁇ e k ⁇ S
  • small increases in skin tone or hematocrit levels could result in larger shifts in the center wavelength, which may be beneficial if absorption by melanin or hemoglobin significantly impacts the therapeutic efficacy at certain levels.
  • a logarithmic relationship may also be used, particularly if the effect of skin tone or hematocrit levels on light absorption diminishes at higher values:
  • the light source and processor circuitry are not limited to causing the light source to emit light within the 430-490 nm wavelength range, but may include additional wavelength ranges. For example, green light (e.g., around 520 nm) may also be used for treating jaundice.
  • the processor circuitry 14 determines the control variables 20 based on the sensed parameters 22 (also referred to as sensor measurements) received from the sensor 16.
  • the sensor 16 may include at least one of a bilirubin sensor for measuring the bilirubin levels of the infant, a hematocrit sensor for measuring the hematocrit levels of the infant, or a photosensor for measuring the skin tone of the infant.
  • the sensed parameters 22 may be received directly or indirectly from a sensor.
  • the sensed parameters 22 may include blood test results that are input into the processor circuitry 14 by a user.
  • the sensed parameters 22 may include the hematocrit levels of the infant. The hematocrit levels may be determined via a blood test and a user may enter the blood test results into the phototherapy system 10.
  • the processor circuitry 14 may alter the control variables 20 such that a center wavelength of the wavelength range increases with high hematocrit levels.
  • the sensed parameters 22 may include the skin tone of the infant (e.g., received from a camera).
  • the processor circuitry 14 may alter the control variables 20 such that a center wavelength of the wavelength range increases with darker skin tones.
  • the sensed parameters 22 may include at least one of the hematocrit levels or the skin tone.
  • the skin tone of the infant may be determined by user input or using a photosensor (such as a camera).
  • the processor circuitry 14 may alter the control variables 20 based on the sensed parameters 22 by calculating as non-therapeutic light a portion of the emitted light that does not contribute to the therapeutic effect.
  • the skin tone may be used to estimate a percentage of the emitted light 18 that is absorbed by the skin as heat.
  • the hematocrit levels may be used to estimate a percentage of the emitted light 18 that is absorbed by red blood cells of the infant.
  • the sensor 16 may utilize a calibrated colorimetric camera or spectrophotometer integrated into the phototherapy system 10. The camera captures images of the infant's skin under standardized lighting conditions to minimize variability.
  • the processor circuitry 14 may analyze these images to quantify the skin tone by measuring the reflectance or absorbance of specific wavelengths of light associated with melanin content. This quantification may involve comparing the measured values against a predefined skin tone scale, such as the Fitzpatrick skin type classification or the Individual Typology Angle (ITA) scale.
  • ITA Individual Typology Angle
  • the processor circuitry 14 may apply image processing algorithms to correct for any ambient lighting effects, ensuring accurate assessment of the skin tone. By converting the skin tone measurements into numerical values representing melanin concentration, the processor circuitry 14 can use this data to adjust the control variables 20 accordingly. The processor circuitry 14 may then alter the control variables 20 to compensate for the estimated non-therapeutic light. That is, higher hematocrit levels and darker skin tones may result in greater absorption of emitted light 18 that does not contribute to the reduction in bilirubin levels. For example, if the estimated non-therapeutic light is 20% (i.e., 20% of the emitted light does not contribute to a therapeutic effect), then the intensity or duration of phototherapy may be altered to increase the optical dosage by 20% to make up for the estimated non-therapeutic light.
  • the processor circuitry 14 may estimate as the non-therapeutic light a percentage of the emitted light 18 absorbed by the blood of the patient based on the hematocrit levels.
  • the processor circuitry may determine wavelength absorption properties of the skin of the infant based on the measured skin tone. The processor circuitry 14 may then determine an overlap of the wavelength range of the emitted light and the determined wavelength absorption properties of the skin. The processor circuitry 14 may use this information to estimate as the non-therapeutic light a percentage of the emitted light absorbed by the skin of the patient based on the determined overlap.
  • the calculation of non-therapeutic light involves estimating the proportion of the emitted light 18 that is absorbed by the infant's skin and blood without contributing to the phototherapy's effectiveness in reducing bilirubin levels.
  • the processor circuitry 14 may use the quantified skin tone data to determine the melanin absorption coefficient at various wavelengths within the emitted light's range. This may be achieved by referencing established optical absorption spectra for melanin.
  • the processor circuitry 14 may then calculates the skin's absorbance Askin( ⁇ ) at each wavelength ⁇ using the formula: where: • ⁇ melanin( ⁇ ) is the wavelength-dependent absorption coefficient of melanin, • C melanin is the concentration of melanin derived from the skin tone measurement, • d is the path length through the skin.
  • the processor circuitry 14 may estimate the absorption of light by hemoglobin in the blood based on the hematocrit levels. The hematocrit level provides the volume percentage of red blood cells in the blood, which correlates with the concentration of hemoglobin.
  • the absorbance Ablood( ⁇ ) at each wavelength may be calculated using: where: • ⁇ hemoglobin( ⁇ ) is the absorption coefficient of hemoglobin at wavelength ⁇ lambda ⁇ , • C hemoglobin is the concentration of hemoglobin estimated from the hematocrit level, • d is the path length through the blood.
  • the processor circuitry 14 may opt to emit light at wavelengths less absorbed by melanin or hemoglobin while still effective for bilirubin reduction.
  • the sensor 16 may include a photosensor for measuring the skin tone of the infant.
  • the processor circuitry 14 may determine a change in jaundice level of the infant by receiving the skin tone as the sensed parameters 22 at two different time points. The processor circuitry 14 may then use this information to measure a change in a yellow content of the skin tone between the two different time points.
  • the processor circuitry 14 may then adjust the control variables 20 based on the determined change in the jaundice level of the infant, such that a reduction in the jaundice level of the infant results in a decrease in an optical dose received by the infant over a duration of time.
  • the sensor 16 may include a camera (e.g., a machine vision sensor) for determining an area of the infant illuminated during phototherapy.
  • the processor circuitry 14 may use the output of the camera to determine an optical dose received by the infant per unit of time. That is, the processor circuitry 14 may receive the output of the camera and determine an area of the infant illuminated by the emitted light. The processor circuitry 14 may then determine an optical dose received by the infant based on the determined area of the infant illuminated.
  • the processor circuitry 14 may calculate an area (e.g., in cm 2 ) illuminated by the camera and multiply this calculated area by the intensity of the emitted light and a time duration that the infant was illuminated by the light.
  • the processor circuitry 14 may periodically calculate the area to take into account changes in the area illuminated (e.g., due to the infant moving) when calculating the optical dose received by the infant.
  • the processor circuitry 14 may use this information to vary the intensity of the emitted light and a length/duration of time of the phototherapy session (i.e., how long the infant is illuminated with light).
  • the sensor 16 includes an identification sensor for detecting an identification band (e.g., an RFID wrist band) on the infant.
  • the processor circuitry 14 may determine an amount of time the infant is located within an area illuminated by the emitted light based on the detection of the identification band.
  • the sensor 16 includes a transcutaneous bilirubin sensor for measuring the bilirubin levels of the infant (also referred to as transcutaneous bilirubin (TcB)).
  • the processor circuitry 14 may receive the output of the transcutaneous bilirubin sensor and blood bilirubin levels measured using a blood test to calibrate the transcutaneous bilirubin sensor.
  • the bilirubin sensor may continuously monitor bilirubin levels.
  • the sensor 16 may also sense at least one of the skin tone or the hematocrit levels of the infant.
  • the processor circuitry 14 may continuously alter the control variables 20 to affect an intensity and a center wavelength of the wavelength range of the emitted light based on the bilirubin levels and at least one of the skin tone or hematocrit levels.
  • the processor circuitry may also alter an illumination schedule of the light source based on time of day. That is, the processor circuitry 14 may also alter the control variables 20 based on the time of day, such that the wavelength range and intensity of the emitted light 18 synchronizes with a circadian rhythm of the infant.
  • the control variables 20 may cause the emitted light 18 to include longer wavelengths in the wavelength range closer to sunset compared to midday.
  • the emitted light 18 may include shorter wavelengths in the wavelength range closer to sunrise compared to midday.
  • the emitted light 18 may have a higher intensity at midday compared to sunset.
  • the processor circuitry 14 may modify the schedule of light illumination (i.e., when phototherapy is applied throughout the day). This feature may enable the adaptation of phototherapy sessions to align with hospital staffing schedules, allowing treatments to be administered over one or two shifts, as opposed to a more fragmented approach.
  • the processor circuitry 14 may receive (1) a time duration corresponding to a shift schedule of medical personnel and (2) a desired optical dose.
  • the processor circuitry 14 may alter the control variables 20 based on the received time duration and the received desired optical dose, such that the infant receives the desired optical dose of the emitted light within the time duration.
  • the light source 12 may have various implementations.
  • the light source 12 may include any suitable device capable of emitting light within the desired wavelength range for phototherapy treatment, such as light-emitting diodes (LEDs), organic LEDs (OLEDs), laser diodes, fluorescent lamps, halogen lamps, fiber optic illuminators, or other suitable light-emitting components.
  • the light source 12 may be designed to emit light with adjustable properties, including wavelength, intensity, timing, and duration of illumination, as controlled by the processor circuitry 14. It may incorporate optical elements such as lenses, filters, diffusers, reflectors, or collimators to shape and direct the emitted light toward the infant effectively.
  • the light source 12 may also include driver circuits, power supplies, cooling systems, and other ancillary components necessary for its operation.
  • the light source 12 may be communicatively coupled to the processor circuitry 14 through wired connections like electrical conductors or circuit boards, or wirelessly using suitable communication protocols. It can be integrated into the phototherapy system as a built-in unit or configured as a modular component that can be replaced or upgraded as needed.
  • the sensor 16 may have various implementations.
  • the sensor 16 may include any suitable device for measuring the sensed parameters, such as a photodetector, photodiode, phototransistor, spectrometer, colorimeter, camera, optical sensor, or other suitable sensing devices.
  • the sensor 16 may be configured to detect at least one of the bilirubin levels in the infant, the skin tone of the infant, or the hematocrit levels of the infant. This may involve the use of transcutaneous bilirubin sensors, optical skin sensors, hematocrit sensors, or other suitable sensors known in the art.
  • the sensor 16 may also include associated circuitry such as amplifiers, filters, analog-to-digital converters, or other signal conditioning components necessary to process the sensor signals for use by the processor circuitry 14. Additionally, the sensor 16 may be communicatively coupled to the processor circuitry 14, either directly or via suitable interfaces like a system bus or network interface, to transmit the sensed parameters for processing.
  • the sensor 16 may be powered by the system's power supply or may have its own power source, such as a battery.
  • the processor circuitry 14 may have various implementations.
  • the processor circuitry 14 may include any suitable device, such as a processor (e.g., CPU), programmable circuit, integrated circuit, memory and I/O circuits, an application specific integrated circuit, microcontroller, complex programmable logic device, other programmable circuits, or the like.
  • the processor circuitry 14 may also include a non-transitory computer readable medium, such as random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), or any other suitable medium.
  • Instructions for performing the method described below may be stored in the non- transitory computer readable medium and executed by the processor circuitry 14.
  • the processor circuitry 14 may be communicatively coupled to the computer readable medium and network interface through a system bus, mother board, or using any other suitable structure known in the art. All ranges and ratio limits disclosed in the specification and claims may be combined in any manner. Unless specifically stated otherwise, references to “a,” “an,” and/or “the” may include one or more than one, and that reference to an item in the singular may also include the item in the plural. Although the invention has been shown and described with respect to a certain embodiment or embodiments, equivalent alterations and modifications will occur to others skilled in the art upon the reading and understanding of this specification and the annexed drawings.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Est proposé un système de photothérapie pour traiter la jaunisse néonatale chez un nourrisson par commande de la photothérapie sur la base des propriétés du nourrisson. Le système comprend un circuit de processeur pour modifier des variables de commande reçues par une source de lumière sur la base de mesures de capteur de niveaux de bilirubine, de ton de la peau ou de niveaux d'hématocrite.
PCT/US2024/054102 2023-11-02 2024-11-01 Dispositif de photothérapie à commutation de longueur d'onde Pending WO2025096929A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363595434P 2023-11-02 2023-11-02
US63/595,434 2023-11-02

Publications (1)

Publication Number Publication Date
WO2025096929A1 true WO2025096929A1 (fr) 2025-05-08

Family

ID=93648544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/054102 Pending WO2025096929A1 (fr) 2023-11-02 2024-11-01 Dispositif de photothérapie à commutation de longueur d'onde

Country Status (1)

Country Link
WO (1) WO2025096929A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018622A1 (en) * 2006-02-06 2009-01-15 Koninklijke Philips Electronics N.V. Body cover, glasses and/or at least partial head cover, method for radiating at least part of a human body and use of a body cover
CN107213555A (zh) * 2017-08-01 2017-09-29 中国科学院大学 用于治疗新生儿黄疸的激光光疗屋智能系统
WO2019070116A1 (fr) * 2017-10-02 2019-04-11 Universiti Telekom Sdn. Bhd. Système intelligent de diagnostic et de traitement automatisés d'ictère néonatal
WO2019206929A2 (fr) * 2018-04-27 2019-10-31 Koninklijke Philips N.V. Procédé et dispositif de surveillance et de prédiction en temps réel de niveaux de bilirubine et notifications associées chez les nouveaux-nés

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018622A1 (en) * 2006-02-06 2009-01-15 Koninklijke Philips Electronics N.V. Body cover, glasses and/or at least partial head cover, method for radiating at least part of a human body and use of a body cover
CN107213555A (zh) * 2017-08-01 2017-09-29 中国科学院大学 用于治疗新生儿黄疸的激光光疗屋智能系统
WO2019070116A1 (fr) * 2017-10-02 2019-04-11 Universiti Telekom Sdn. Bhd. Système intelligent de diagnostic et de traitement automatisés d'ictère néonatal
WO2019206929A2 (fr) * 2018-04-27 2019-10-31 Koninklijke Philips N.V. Procédé et dispositif de surveillance et de prédiction en temps réel de niveaux de bilirubine et notifications associées chez les nouveaux-nés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLAVSKII V YU ET AL: "Spectral Range Optimization to Enhance the Effectiveness of Phototherapy for Neonatal Hyperbilirubinemia", JOURNAL OF APPLIED SPECTROSCOPY, NEW YORK,NY, US, vol. 84, no. 1, 18 April 2017 (2017-04-18), pages 92 - 102, XP036219822, ISSN: 0021-9037, [retrieved on 20170418], DOI: 10.1007/S10812-017-0433-3 *

Similar Documents

Publication Publication Date Title
JP5671460B2 (ja) 分光センサ
CA2605467C (fr) Systemes et procedes de correction de mesures de reflectance optique
KR102033914B1 (ko) 혈당 측정방법 및 이를 이용한 인체착용형 혈당 측정장치
US20080132771A1 (en) Measurement of blood oxygen saturation
US20090270848A1 (en) Optical Sensor and Method for Identifying the Presence of Skin and the Pigmentation of Skin
US20210236844A1 (en) A method and device for real time monitoring and prediction of bilirubin levels and associated notifications in neonates
WO2012011042A2 (fr) Améliorations en photothérapie
WO2012011013A2 (fr) Améliorations relatives à la photothérapie
US20220117525A1 (en) Sensor and system for neonatal jaundice monitoring and management
Le et al. Review of modern techniques in detecting port-wine stain response to laser therapy
CN112137624A (zh) 血氧饱和度的测定方法
WO2025096929A1 (fr) Dispositif de photothérapie à commutation de longueur d'onde
WO2012011009A1 (fr) Améliorations apportées à la photothérapie
CN110876836B (zh) 光疗控制装置
CN114599311A (zh) 牙齿美白系统
US11980773B2 (en) Tunable light source
EP3135198B1 (fr) Photomètre pour mesurer le pouls et procédé d'évaluation de la fiabilité de la valeur calculée de la concentration de l'absorbeur de lumière de sang
JP3016160U (ja) 近赤外線無侵襲生体計測装置
JP2007506522A (ja) 血液酸素飽和度の測定
US20250359814A1 (en) Skin characterization device and method
US20250050129A1 (en) Systems and methods for determining minimal erythema dose for phototherapy
KR20250017942A (ko) 사용자 맞춤형 맥파 측정 장치 및 이를 이용한 실시간 스트레스 모니터링 시스템 및 방법
Soller et al. i, United States Patent (10) Patent No.: US 8873035 B2
Kviesis-Kipge et al. Multimodal imaging device for skin diagnostics: improvements and tests

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24812270

Country of ref document: EP

Kind code of ref document: A1